The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience.
Oncology
; 94(3): 161-166, 2018.
Article
em En
| MEDLINE
| ID: mdl-29241166
ABSTRACT
BACKGROUND/AIM:
Prostate cancer frequently causes bone metastases and skeletal events that impair quality of life (QoL) and survival. The alpha emitter radium-223 is a new drug that improves treatment in men with castration-resistant prostate cancer (CRPC) and bone metastases. Our aim was to evaluate the effectiveness of radium-223. SUBJECTS ANDMETHODS:
In this retrospective study we enrolled 48 subjects. Pain reduction, alkaline phosphatase (ALP), time to first symptomatic skeletal event, and QoL were the variables we evaluated.RESULTS:
Radium-223 was well tolerated, with a manageable toxicity profile and a modest objective response rate. A considerable difference in serum ALP levels before and after treatment was observed, with a significant correlation between pain relief and QoL, which showed a value of R2 to 0.44 with a slope of 1.50 (p = 0.0021).CONCLUSIONS:
Radium-223 showed a clinical benefit, with a reduction in pain symptoms in 58% of patients. Radium-223 was shown to be an effective and well-tolerated therapeutic option in patients with metastatic CRPC progressing after docetaxel plus prednisone treatment.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Radioisótopos
/
Neoplasias Ósseas
/
Rádio (Elemento)
/
Neoplasias de Próstata Resistentes à Castração
/
Antineoplásicos
Tipo de estudo:
Observational_studies
Limite:
Aged
/
Aged80
/
Humans
/
Male
/
Middle aged
País como assunto:
Europa
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article